MultiPlan Selects Oracle Cloud Infrastructure to Power its Business Transformation

MultiPlan Selects Oracle Cloud Infrastructure to Power its Business Transformation

MultiPlan consolidates cloud infrastructure to establish a scalable foundation for growth, bring new products to market faster and better support its clients and the patients and members they serve with solutions that improve affordability, quality, and transparency.

NEW YORK–(BUSINESS WIRE)–
MultiPlan Corporation (NYSE: MPLN), a leading provider of technology and data solutions that improve affordability, quality and transparency in healthcare, will consolidate its cloud infrastructure on Oracle Cloud Infrastructure (OCI) to support its previously disclosed digital transformation. OCI will also help MultiPlan better support its clients’ needs by improving efficiency and creating a more flexible infrastructure that meets evolving market demands.

“Migrating to OCI is critical to achieving our vision and will enable us to leverage our expertise and data to deliver new solutions that serve a broader set of healthcare stakeholders,” said Travis Dalton, President and Chief Executive Officer of MultiPlan. “Our clients will be able to better serve their patients and members with modern solutions.”

MultiPlan will begin its migration to OCI with a “lift-and-shift” of its existing on-premises workloads, including a large Oracle Database footprint. OCI helps make cloud migrations faster and lowers risk by minimizing application changes while maximizing infrastructure price-performance. Over time, MultiPlan plans to move workloads currently on other platforms to OCI to take advantage of significant cost savings and performance gains. “As we evaluated our options, the team compared current state, other vendor alternatives, and Oracle’s next-generation cloud. The winner was clear – OCI provides best-in-class security with the performance, technical flexibility, and superior economics we need to rapidly innovate to meet our clients’ needs,” said Michael Kim, Chief Information Officer of MultiPlan.

“Healthcare organizations around the world are increasingly realizing the value of migrating to the cloud to enable greater security, agility, and innovation,” said Karan Batta, Senior Vice President, Oracle Cloud Infrastructure. “By selecting OCI, MultiPlan gains a cloud partner with significant healthcare industry expertise, compelling price-performance advantages, and a proven track record of protecting the world’s most sensitive data. OCI provides the foundation MultiPlan needs to accelerate the realization of its vision and take advantage of the latest developments in analytics and AI.”

About MultiPlan

MultiPlan is committed to bending the cost curve in healthcare by delivering transparency, fairness, and affordability to the US healthcare system. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets clients’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based, data and decision science, and analytics-based services. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit multiplan.com.

Media Relations Contact

Pamela Walker

AVP, Marketing & Communication

781-895-3118

[email protected]

Investor Relations Contacts

Jason Wong

SVP, Treasury & Investor Relations

866-909-7427

[email protected]

Shawna Gasik

AVP, Investor Relations

866-909-7427

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Technology Health Insurance Apps/Applications Professional Services Artificial Intelligence Practice Management Software Managed Care Data Analytics Internet Health Technology Health Insurance Data Management

MEDIA:

Logo
Logo

NV5 Enters Agreement to Acquire Group Delta; Strengthens Southern California Infrastructure Engineering, Testing, and Environmental Services

HOLLYWOOD, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) — NV5, a provider of technology, certification, and consulting solutions, announced today that it has entered into an agreement to acquire Group Delta, a provider of infrastructure engineering, testing, and environmental PFAS services. Headquartered in Irvine, California, Group Delta specializes in large scale water, electrical utility, and transportation infrastructure throughout Southern California.

Group Delta’s 100 employees operate out of five consulting and testing laboratories in Los Angeles, Orange, and San Diego counties, delivering geotechnical engineering, materials testing, special inspections, forensics engineering, and environmental PFAS and compliance consulting. The acquisition strengthens NV5’s infrastructure engineering, conformity assessment, and utility fire hardening capabilities in the region.

“The combined capabilities of NV5 and Group Delta provide a strong competitive advantage when pursuing large scale electrical, water, and transportation infrastructure improvement projects, and we look forward to contributing to the success of these infrastructure projects across the region,” said Ben Heraud, CEO of NV5.

“California recently committed to investing $180 billion to improve the state’s infrastructure, including once in a generation energy, water, and transportation improvements. Recent events in Southern California have demonstrated the need to improve the state’s critical infrastructure, and we are pleased to strengthen NV5’s capabilities to support our city, county, state, and utility clients throughout Southern California,” said Dickerson Wright, PE, Executive Chairman of NV5.

“All of us at Group Delta are excited about the career opportunities that NV5 presents for our employees and the new services we can now offer to our clients,” said Shah Ghanbari, PE, President of Group Delta.

“We are excited to join NV5 and look forward to expanding our long-standing client relationships with NV5’s complete portfolio of conformity assessment, engineering design, and tech-enabled services,” said Mike Reader, PE, CEO of Group Delta.

About Group Delta

Founded in 1986, Group Delta has provided geotechnical engineering, environmental PFAS consulting, materials testing, special inspections, and construction support services for more than 30 years.   Group Delta is staffed by 100 civil and geotechnical engineers, environmental engineers and scientists, geologists, laboratory and field technicians, deputy grading and construction inspectors, and CAD designers. Group Delta maintains offices in the cities of Irvine, Torrance, Anaheim, San Diego, and Ontario as well as accredited laboratories in San Diego and Anaheim.   For additional information, please visit www.groupdelta.com.

About NV5

NV5 Global, Inc. (NASDAQ: NVEE) is a provider of technology, certification, and consulting solutions for public and private sector clients supporting utility, infrastructure, and building assets and systems. The Company primarily focuses on six business verticals: Utility services, infrastructure support, conformity assessment, buildings & technology, environmental health sciences, and geospatial services. NV5 operates out of more than 100 offices nationwide and abroad. For additional information, please visit the Company’s website at www.NV5.com. Also visit the Company on Twitter, LinkedIn, Facebook, and Vimeo.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The Company cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained in this news release. Such factors include: (a) changes in demand from the local and state government and private clients that we serve; (b) general economic conditions, nationally and globally, and their effect on the market for our services; (c) competitive pressures and trends in our industry and our ability to successfully compete with our competitors; (d) changes in laws, regulations, or policies; and (e) the “Risk Factors” set forth in the Company’s most recent SEC filings. All forward-looking statements are based on information available to the Company on the date hereof, and the Company assumes no obligation to update such statements, except as required by law.

Investor Relations Contact

NV5 Global, Inc.
Jack Cochran
Vice President, Marketing & Investor Relations
Tel: +1-954-637-8048
Email: [email protected]

Source: NV5 Global, Inc.



KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter

KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter

MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024.

Financial Results (unaudited)

  • Preliminary, unaudited fourth quarter 2024 net revenues expected to be $8.9 million, representing growth of 23% over the prior year period

  • Preliminary, unaudited full year 2024 net revenues expected to be $33.7 million, representing growth of 18% over the prior year

  • Ending cash balance of $9.6 million, representing positive cash flow of $0.8 million for the fourth quarter and full year cash burn of $1.9 million, a 67% improvement over the prior year

“I am proud of the growth that we have achieved in our fourth quarter and 2024 finish,” said Linda Tharby, President and CEO of KORU Medical. “We executed on all aspects of our strategic plan as we continued to win share in the US market, expanded our international footprint, and made meaningful progress towards adding new drug therapies to our label. We did this as we continued to improve margins and demonstrated a disciplined use of cash. We are excited by our fourth quarter momentum that we will carry into 2025 as we look to capitalize on near-term catalysts that will continue to transform KORU into a global leader in drug delivery.”

KORU plans to release its fourth quarter and full year 2024 financial results in early March 2025. The quarterly and annual preliminary revenue figures included in this press release are subject to adjustment following the completion of review and audit procedures by the Company’s independent registered public accountants.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including but not limited to sales expansion into new regions. Actual results may differ materially from these statements due to potential risks and uncertainties such as those risks and uncertainties included under the captions “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 which is on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of April 11, 2024. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Investor Contact:

Louisa Smith

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Other Manufacturing Medical Devices Medical Supplies FDA Clinical Trials Health Technology Manufacturing Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results

Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results

CHICAGO–(BUSINESS WIRE)–
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.

Full Year 2024 Select, Preliminary, Unaudited Financial Results

  • Revenue of approximately $693 million, representing approximately 30% growth year-over-year

  • Continued improvement in adjusted EBITDA compared to the prior year

Fourth Quarter 2024 Select, Preliminary, Unaudited Financial Results

  • Revenue of approximately $200 million, an increase of approximately 35% year-over-year

  • Continued trend of sequential improvement in adjusted EBITDA in the fourth quarter of 2024

“We concluded 2024 with continued strength in our core businesses, as genomics revenue is expected to grow at ~30% in Q4 and our data and services revenue is expected to grow at ~45%, such that we expect to deliver ~99% of our revenue guidance for 2024 and ~100% of our adjusted EBITDA guidance,” said Eric Lefkofsky, Founder and CEO of Tempus. “Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year.”

This announcement comes ahead of the Company’s presentation today at the 43rd Annual J.P. Morgan Healthcare Conference. A live webcast to the presentation and our updated investor deck, which includes an update on the expected closing of our Ambry acquisition, can be found on our investor relations website at investors.tempus.com.

Tempus has not completed preparation of its financial statements for the fourth quarter or full year 2024. The estimates disclosed in this release for the fourth quarter and year ended December 31, 2024, are preliminary, and unaudited and inherently uncertain, and therefore subject to change as Tempus completes preparation of its financial results for these periods. Tempus is in the process of completing its customary year-end close and review procedures for the quarter and year ended December 31, 2024, and there can be no assurance that final results for these periods will not differ from these estimates, and any such difference may be material. During the preparation of Tempus’ consolidated financial statements for the year ended December 31, 2024, Tempus or its independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.

Tempus plans to report its complete fourth quarter and full year 2024 financial results during its first earnings call of 2025.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Non-GAAP Financial Measures

In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents the non-GAAP financial measure Adjusted EBITDA. Adjusted EBITDA is defined as net income (loss), adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses on equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) stock-based compensation expense, (viii) employer payroll tax related to stock-based compensation expense, (ix) the payment of $2.3 million of our Series G-4 convertible preferred stock in connection with the initial public offering, and (x) amortization of deferred other income from our IP License Agreement with SB Tempus.

Tempus believes this non-GAAP financial measure is useful to investors and others because it allows for additional information with respect to financial measures used by management in its financial and operational decision-making and it may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and Adjusted EBITDA should be considered in addition to, not as a substitute for or in isolation from, net loss, the most comparable GAAP measure. Other companies, including companies in our industry, may calculate this non-GAAP financial measure differently or not at all, which reduces its usefulness as a comparative measure.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ preliminary, unaudited financial results for fourth quarter and full year 2024; Tempus’ expected financial results for full year 2025; the contributions of Tempus’ research and findings to the larger scientific community, the use of Tempus’ products and services to advance clinical care for patients, and the pending acquisition of Ambry. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including our ability to consummate the acquisition of Ambry Genetics and the related financing on the terms described herein or at all and, if consummated, to realize the expected benefits of such acquisition; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) on November 4, 2024, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Erin Carron

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Health Technology Health Technology Software General Health Artificial Intelligence

MEDIA:

Logo
Logo

Sprinklr Appoints Tech Executive Joy Corso as Chief Administrative Officer

Sprinklr Appoints Tech Executive Joy Corso as Chief Administrative Officer

NEW YORK–(BUSINESS WIRE)–Sprinklr (NYSE: CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced the appointment of Joy Corso as Chief Administrative Officer, effective immediately. Corso will report to Sprinklr President and CEO, Rory Read.

In this new role, Corso will lead both the Marketing and Culture & Talent organizations, with a focus on strengthening market position, customer and employee engagement, talent development, and culture change to advance the company’s leadership position.

“We are thrilled to welcome Joy to the Sprinklr team. Her experience in the enterprise space, strong leadership, and proven track record driving business and culture transformation will be a valuable addition to our Executive Leadership Team,” said Sprinklr President and CEO, Rory Read. “While we have significant work ahead, we are taking the right steps to unlock our full potential. Joy’s extensive experience in the B2B tech industry, as well as her focus on delivering operational efficiencies and scale, will fundamentally support our next phase of growth. We have a clear focus on our ambidextrous strategy to reenergize and grow our Sprinklr Core while we harden and expand Sprinklr Service and help customers realize the full value of our AI-powered platform.”

Corso brings more than 25 years of global experience across industries. She joins Sprinklr from Vonage, where she served as Chief Marketing Officer. Her previous experience includes leadership roles in notable companies including Virtustream (a Dell Technologies Company), Advanced Micro Devices, Raytheon, and Fidelity Investments.

“I am truly delighted to be joining Sprinklr, particularly at such a pivotal point in its evolution,” said Corso. “Sprinklr’s vision is inspiring, and its platform that helps enterprises engage with audiences in unique and disruptive ways is a powerful proposition in an ever-increasing competitive marketplace. I’m excited to work with the Executive Leadership Team and our talented Sprinklr teammates across the globe to help innovate and scale to bring even more value to our customers all over the world.”

Also effective on January 13, 2025, Diane Adams will be leaving her role as Chief Culture and Talent Officer and will continue in an advisory capacity until February 14, 2025.

“We are grateful for Diane’s thoughtful leadership and vision, which has been instrumental in guiding our culture and growth from a private company to the organization we are today. Her contributions have laid an important foundation for our journey ahead,” said Read.

About Sprinklr

Sprinklr is a leading enterprise software company for all customer-facing functions. With advanced AI, Sprinklr’s unified customer experience management (Unified-CXM) platform helps companies deliver human experiences to every customer, every time, across any modern channel. Headquartered in New York City with employees around the world, Sprinklr works with more than 1,800 valuable enterprises — global brands like Microsoft, P&G, Samsung and more than 60% of the Fortune 100. Sprinklr’s value to the enterprise is simple: We un-silo teams to make customers happier.

Forward Looking Statements

This press release contains forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential benefits of appointing Joy Corso as Sprinklr’s Chief Administrative Officer. By their nature, forward-looking information and statements are subject to risks, uncertainties, and contingencies, including (i) the risk that the potential benefits of Ms. Corso’s appointment are not realized and (ii) risks, uncertainties and contingencies that may apply to Sprinklr’s business. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are discussed in our Quarterly Report on Form 10-Q for the quarter ended October 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on December 4, 2024, under the caption “Risk Factors,” and in other filings that we make from time to time with the SEC. Sprinklr does not undertake to update any forward-looking statements or information, including those contained in this press release.

Press Contact

Austin DeArman

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software Mobile/Wireless Social Media Professional Services Online Retail Internet Business Technology Artificial Intelligence Retail Marketing Communications Consulting

MEDIA:

Logo
Logo

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

WALTHAM, Mass. & SAN DIEGO–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity’s recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and strengthens Element’s momentum towards regulatory approval of the benchtop AVITI™ sequencing system.

The collaboration involves the co-development of a comprehensive IVD solution tailored for newborn sequencing. Additionally, customers will have immediate access to a research use only (RUO) version of the newborn sequencing research workflow.

“This strategic endeavor represents a significant step forward in our commitment to advancing newborn health through innovative genomic technologies,” said Yves Dubaquie, senior vice president, diagnostics at Revvity. “By combining our expertise in newborn screening and rare disease detection with Element’s technological capabilities, Revvity aims to deliver a robust, efficient, and accessible solution for neonatal sequencing in both research and clinical settings.”

The new IVD solution offered by Revvity will be an important organic next step for each company, expanding the reach of both Element’s AVITI sequencing system and Revvity’s newborn sequencing research workflow, which includes its sample collection devices, dried blood spot punchers, automated nucleic acid extractors, liquid handers, NGS library preparation kits with carefully curated NGS panels, and comprehensive software for variant calling data analysis and interpretation. The combined technologies will provide an end-to-end solution for the NGS continuum that supports pioneering neonatal research and the necessary approvals for a cutting-edge IVD in this field.

“Collaboration with Revvity on this IVD solution will provide a comprehensive, high-quality offering that meets the unique needs of newborn screening programs worldwide,” said Yaron Hakak, senior vice president of corporate and business development at Element. “Element is committed to seeking AVITI’s regulatory approval to enable the introduction of new diagnostic solutions from Revvity and other market leading partners.”

For more information about Revvity’s newborn sequencing research solutions, please visit: https://www.revvity.com/gb-en/category/newborn-sequencing-research

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

About Element Biosciences, Inc.

Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Revvity Investor Relations:

Steve Willoughby

[email protected]

Revvity Media Relations:

Chet Murray

(781) 462-5126

[email protected]

Element Media Relations:

[email protected]

KEYWORDS: California Massachusetts United States North America

INDUSTRY KEYWORDS: Software Research General Health Pharmaceutical Data Management Consumer Technology Medical Devices Genetics Science Baby/Maternity Biotechnology Health

MEDIA:

Logo
Logo

nbkc bank Selects NCR Atleos Allpoint to Expand Access to Self-Service Banking

nbkc bank Selects NCR Atleos Allpoint to Expand Access to Self-Service Banking

ATLANTA–(BUSINESS WIRE)–NCR Atleos Corporation (NYSE: NATL) (“Atleos”), a leader in expanding self-service financial access for financial institutions, retailers and consumers, today announced that $1.1 billion-asset nbkc bank has selected Atleos’ Allpoint Network to provide expanded, more convenient access to everyday banking transactions for its customers.

Kansas City, Missouri-based nbkc was looking for an efficient way to allow customers to conduct transactions at convenient retail locations across the United States. By joining Atleos’ Allpoint Network, nbkc bank was able to quickly and easily provide surcharge-free access to an additional 55,000 ATMs worldwide, in addition to the other ATMs they already have access to, in trusted retail locations across the country where customers already live and shop. Additionally, nbkc bank customers will have a co-branded digital experience during ATM transactions and be able to deposit cash at more than 3,000 locations in the Allpoint Network.

“We aimed to leverage intuitive technology to enhance convenient and exceptional customer experiences,” said Melissa Eggleston, Chief Deposit and Operations Officer at nbkc bank. “Our collaboration with Atleos effectively extends our branch network by providing greater access to self-service banking through an expanded ATM network. This ATM network expansion ensures our customers can conveniently deposit cash and perform other transactions at ATMs located in retail locations where they already shop, offering the same exceptional – and on-brand – service they expect from nbkc.”

“Our utility ATM network provides increased efficiencies for financial institutions and expanded financial access for their customers,” explained Steven Nogalo, General Manager of North America for Atleos. “We look forward to teaming up with nbkc bank, to provide physical banking touchpoints for their customers in retail locations they know and trust.”

About Atleos

Atleos (NYSE: NATL) is a leader in expanding self-service financial access, with industry-leading ATM expertise and experience, unrivalled operational scale including the largest independently-owned ATM network, always-on global services and constant innovation. Atleos improves operational efficiency for financial institutions, drives footfall for retailers and enables digital-first financial self-service experiences for consumers. Atleos is headquartered in Atlanta, Georgia, with approximately 20,000 employees globally.

Web site: https://www.ncratleos.com

X (Twitter): https://twitter.com/ncratleos

Facebook: https://www.facebook.com/Atleos.NCR/

LinkedIn: https://www.linkedin.com/company/ncratleos

YouTube: https://www.youtube.com/@ncratleos

Instagram: https://www.instagram.com/ncratleos/

About nbkc

Marking its 25th anniversary in 2024, nbkc is a diversified banking company known for combining intuitive technology and personal support to create exceptional client experiences. We offer online mortgage and consumer banking nationally; community and commercial banking throughout our home region of Kansas City; and banking as a service to fintech companies across the U.S. Formed in 1999, nbkc continues to pursue its mission of leading the industry to simpler and more transparent banking. Member FDIC. Equal Housing Lender. Learn more about us at nbkc.com.

Scott Sykes

NCR Atleos

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Software Finance Banking Data Management Professional Services Technology Fintech Other Technology

MEDIA:

Logo
Logo

BARK Reports Preliminary Third Quarter Fiscal Year 2025 Results

BARK Reports Preliminary Third Quarter Fiscal Year 2025 Results

The Company is scheduled to present at the 2025 ICR Conference today, January 13, 2025, at 4:00 p.m. E.T.

To announce full third quarter fiscal year 2025 results on February 5, 2025 after market

NEW YORK–(BUSINESS WIRE)–
BARK, Inc. (NYSE: BARK) (“BARK” or the “Company”), a leading global omnichannel dog brand with a mission to make all dogs happy, today announced its preliminary financial results for the fiscal third quarter ended December 31, 2024.

Preliminary Financial Results

  • Total revenue was approximately $126.4 million, ahead of the high-end of the Company’s guidance range and a 1.1% increase, year-over-year.

  • Net loss of approximately $(11.5) million, was $1.4 million greater than the same period last year primarily related to a $1.8 million gain from the extinguishment of debt in the year-ago period.

  • Adjusted EBITDA was approximately $(1.6) million, within the Company’s guidance range and a $4.9 million improvement, year-over-year.

“We closed 2024 on a high note, achieving our tenth consecutive quarter of year-over-year growth in Adjusted EBITDA and surpassing our revenue guidance,” said Matt Meeker, Co-Founder and Chief Executive Officer. “During the quarter, we migrated all of our paid media to the BARK.co platform, and the initial results exceeded our expectations. Building on this early success, we strategically increased our marketing investment during the period to further capitalize on the momentum, driving 8% year-over-year growth in new subscribers.” Meeker continued, “We also saw encouraging progress on BARK Air, which delivered $2 million of revenue in the quarter. This progress, coupled with continued growth in our commerce segment, which is up over 25% year-to-date, provide strong momentum as we look ahead to fiscal 2026.”

The preliminary financial results provided above are based on the company’s current estimate of its fiscal third quarter 2025 results and remain subject to change based on completion of financial review of the quarter and the execution of internal controls and financial reporting.

The Company intends to reports its full financial results after market on February 5, 2025. Management will host a live conference call and webcast to discuss the Company’s financial results at 4:30 p.m. ET the same day.

Full Year Fiscal 2025 Financial Outlook

Based on current market conditions as of January 13, 2025, BARK is reaffirming its guidance for revenue and Adjusted EBITDA, which is a Non-GAAP financial measure, as follows.

For the fiscal year 2025, the Company is reaffirming its guidance of:

  • Total revenue of $490 million to $500 million, reflecting year-over-year growth of flat to 2.0%.

  • Adjusted EBITDA of $1.0 million to $5.0 million, reflecting a year-over-year improvement of $11.6 million to $15.6 million.

We do not provide guidance for Net Loss due to the uncertainty and potential variability of certain items, including stock-based compensation expenses and related tax effects, which are the reconciling items between Net Loss and Adjusted EBITDA. Because such items cannot be calculated or predicted without unreasonable efforts, we are unable to provide a reconciliation of Adjusted EBITDA to Net Loss. However, such items could have a significant impact on Net Loss.

The guidance provided above constitutes forward looking statements and actual results may differ materially. Please refer to the “Forward Looking Statements” section below for information on the factors that could cause our actual results to differ materially from these forward looking statements and “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Presentation Information

Matt Meeker and Zahir Ibrahim, Chief Financial Officer, are scheduled to participate in a fireside chat at the 2025 ICR Conference in Orlando, Florida, today, January 13, 2025, at 4:00 p.m. Eastern Time.

The audio portion of the fireside chat will be webcast live over the internet and can be accessed at investors.bark.co. An online archive will be available for a period of 90 days following the presentation.

About BARK

BARK is the world’s most dog-centric company, devoted to making all dogs happy with the best products, services, and content. BARK’s dog-obsessed team leverages its unique, data-driven understanding of what makes each dog special to design playstyle-specific toys, wildly satisfying treats, dog-first experiences that foster the health and happiness of dogs everywhere, and more. Founded in 2011, BARK loyally serves millions of dogs nationwide with BarkBox and Super Chewer, its themed toys and treats subscriptions; custom product collections through its retail partner network, including Target, Chewy, and Amazon; and BARK Air, the first air travel experience designed specifically for dogs first. At BARK, we want to make dogs as happy as they make us because dogs and humans are better together. Sniff around at bark.co for more information.

Forward Looking Statements

This press release contains forward-looking statements relating to, among other things, the future performance of BARK that are based on the Company’s current expectations, forecasts and assumptions and involve risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. These statements include, but are not limited to, statements about future operating results, including our strategies, plans, commitments, objectives and goals. Actual results could differ materially from those predicted or implied and reported results should not be considered as an indication of future performance. Other factors that could cause or contribute to such differences include, but are not limited to, risks relating to the uncertainty of the projected financial information with respect to BARK; the risk that spending on pets may not increase at projected rates; that BARK subscriptions may not increase their spending with BARK; BARK’s ability to continue to convert social media followers and contacts into customers; BARK’s ability to successfully expand its product lines and channel distribution; competition; the uncertain effects of global or macroeconomic events or challenges.

More information about factors that could affect BARK’s operating results is included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s quarterly report on Form 10-Q, copies of which may be obtained by visiting the Company’s Investor Relations website at https://investors.bark.co/ or the SEC’s website at www.sec.gov. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to the Company on the date hereof. The Company assumes no obligation to update such statements.

Non-GAAP Financial Measures

We report our financial results in accordance with U.S. GAAP. However, management believes that certain non-GAAP financial measures provides investors with additional useful information in evaluating our performance.

We calculate Adjusted EBITDA as net loss, adjusted to exclude: (1) interest income, (2) interest expense, (3) depreciation and amortization, (4) stock-based compensation expense, (5) change in fair value of warrants and derivatives, (6) capitalized cloud computing amortization, (7) sales and use tax income, (8) restructuring charges related to reduction in force payment, (9) litigation expenses, (10) warehouse restructuring costs, (11) technology modernization costs and other items.

The Non-GAAP Measures are financial measures that are not required by, or presented in accordance with U.S. GAAP. We believe that the Non-GAAP Measures, when taken together with our financial results presented in accordance with U.S. GAAP, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of the Non-GAAP Measures are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation and evaluating our operating performance, as well as for internal planning and forecasting purposes.

The Non-GAAP Measures are presented for supplemental informational purposes only, have limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. Some of the limitations of the Non-GAAP Measures include that (1) the measures do not properly reflect capital commitments to be paid in the future, (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA and Adjusted EBITDA Margin do not reflect these capital expenditures, (3) Adjusted EBITDA does not consider the impact of stock-based compensation expense, which is an ongoing expense for our company, (4) Adjusted EBITDA does not reflect other non-operating expenses, including interest expense. In addition, our use of the Non-GAAP Measures may not be comparable to similarly titled measures of other companies because they may not calculate the Non-GAAP Measures in the same manner, limiting their usefulness as a comparative measure. Because of these limitations, when evaluating our performance, you should consider the Non-GAAP Measures alongside other financial measures, including our net income (loss) and other results stated in accordance with U.S. GAAP.

The reconciliation below is to preliminary net income and management has not completed its review of all items which are components of net loss; therefore, actual results could differ significantly. The following table reconciles the preliminary Adjusted EBITDA of $(1.6) million to the preliminary net loss of $(11.5) million, the most directly comparable financial measure stated in accordance with U.S. GAAP, for the three months ended December 31, 2024:

Adjusted EBITDA

 

Three Months Ended

December 31,

 

2024

 

(in thousands)

Net Loss

$

(11,509

)

Interest income

 

(1,179

)

Interest expense

 

677

 

Depreciation and amortization expense

 

2,704

 

Stock compensation expense

 

3,873

 

Change in fair value of warrants and derivatives

 

(261

)

Cloud computing amortization

 

174

 

Sales and use tax income (1)

 

(450

)

Restructuring

 

924

 

Litigation expenses (2)

 

468

 

Warehouse restructuring costs

 

2,391

 

Technology Modernization (3)

 

545

 

Other items

 

88

 

Adjusted EBITDA

$

(1,555

)

(1)

Sales and use tax expense relates to recording a liability for sales and use tax we did not collect from our customers. Historically, we had collected state or local sales, use, or other similar taxes in certain jurisdictions in which we only had physical presence. On June 21, 2018, the U.S. Supreme Court decided, in South Dakota v. Wayfair, Inc., that state and local jurisdictions may, at least in certain circumstances, enforce a sales and use tax collection obligation on remote vendors that have no physical presence in such jurisdiction. A number of states have positioned themselves to require sales and use tax collection by remote vendors and/or by online marketplaces. The details and effective dates of these collection requirements vary from state to state and accordingly, we recorded a liability in those periods in which we created economic nexus based on each state’s requirements. Accordingly, we now collect, remit, and report sales tax in all states that impose a sales tax. Subsequently, as certain of these liabilities are waived by tax authorities or the applicable statute of limitations expires, the related accrued liability is reversed.

 

(2)

Litigation expenses related to a putative class action complaint filed by three alleged shareholders in the lawsuit styled Kenville v. Northern Star Sponsor LLC, et al., Case No. 2024-276, which is pending in the Delaware Court of Chancery.

 

(3)

Includes consulting fees related to technology transformation activities, redundant expenses incurred from duplicative technology platforms, and payroll costs for employees that dedicate significant time to this project. We believe that these costs are discrete and non-recurring in nature, as they relate to a one-time unification of our product offerings on our new commerce platform. As such, they are not normal, recurring operating expenses and are not reflective of ongoing trends in the cost of doing business.

 

Investors:

Michael Mougias

[email protected]

Media:

Garland Harwood

[email protected]

KEYWORDS: Florida New York United States North America

INDUSTRY KEYWORDS: Online Retail Retail Other Consumer Consumer Other Retail Specialty Pets

MEDIA:

Logo
Logo

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million

QUEENSBURY, N.Y.–(BUSINESS WIRE)–
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024.

Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unaudited)

  • Total fourth quarter and full year revenue expected to be approximately $15.1 million and $37.2 million, respectively

  • HEPZATO KIT™ fourth quarter and full year revenue expected to be approximately $13.7 million and $32.3 million, respectively

  • CHEMOSAT® fourth quarter and full year revenue expected to be approximately $1.4 million and $4.9 million, respectively

  • Gross margins expected to be in the 80%-85% range

  • As of December 31, 2024, the Company had approximately $53.2 million of cash, cash equivalents and short-term investments and no debt

Final financial results for the fourth quarter and full year 2024 and a detailed business update will be provided during Delcath’s annual financial results release and investor call scheduled for March 6, 2025.

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Preliminary and Unaudited Nature of Reported Results

The Company has not yet completed its financial close process for the fourth quarter and full year 2024 and, as a result, actual results may vary from the estimated preliminary results set forth in this press release due to a number of factors, including audit adjustments and other developments that may arise between now and the time the financial results for the fourth quarter and fiscal year ended December 31, 2024, are finalized. The estimated preliminary financial results have not been audited or reviewed by the Company’s independent registered public accounting firm. These estimates should not be viewed as a substitute for the Company’s full interim or annual audited financial statements.

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: changes to the estimated preliminary results set forth in this press release as a result of audit adjustments and other developments that may arise between now and the time the financial results for the fourth quarter and fiscal year ended December 31, 2024, are finalized; the Company’s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company’s ability to obtain reimbursement for the HEPZATO KIT; and the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company’s filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Investor Relations:

ICR Healthcare

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Biotechnology Medical Devices Health Pharmaceutical Oncology

MEDIA:

American Eagle Outfitters Raises Fourth Quarter Profit Outlook; Holiday Sales Above Expectations with Growth Across Brands

American Eagle Outfitters Raises Fourth Quarter Profit Outlook; Holiday Sales Above Expectations with Growth Across Brands

PITTSBURGH–(BUSINESS WIRE)–
American Eagle Outfitters, Inc. (NYSE: AEO) today announced that fourth quarter-to-date comparable sales, through Saturday, January 4, 2025, are up in the low single digits, tracking ahead of recent guidance of positive 1%. Trends across American Eagle and Aerie were positive.

As a result, the company is raising its fourth quarter outlook, with operating profit expected to be approximately $135 million, up from previous guidance of $125 million to $130 million. This is based on a comparable sales increase of approximately 2%, building on 8% growth last year. As previously discussed, the retail calendar will have an adverse impact on total revenue*, resulting in total revenue down approximately 5%.

“As a top destination for holiday shopping, we achieved record sales in December. We came to market with exciting new product assortments and engaging customer experiences, resulting in growth across brands and selling channels,” commented Jay Schottenstein, AEO’s Executive Chairman of the Board and Chief Executive Officer. “We also remain focused on driving operational efficiencies, putting us on track to deliver high-teens operating profit growth in 2024.”

Shareholder Returns

Fourth quarter-to-date, the company has repurchased 1.5 million shares for $27 million, bringing year-to-date repurchases to 7.5 million shares for $158 million. The company continues to have 22.5 million shares remaining for repurchase under the current authorization.

Year-to-date, the company has returned $231 million in cash to shareholders through a combination of dividends and share repurchases.

*FY24 Quarterly Impact of Retail Calendar

 

1Q

2Q

3Q

4Q

FY24

Revenue Impact

+$15M

+$55M

-$45M

-$85M

-$60M

About American Eagle Outfitters, Inc.

American Eagle Outfitters, Inc. (NYSE: AEO) is a leading global specialty retailer with a portfolio of beloved apparel brands including American Eagle, Aerie, OFFL/NE by Aerie, Todd Snyder and Unsubscribed. Rooted in optimism, inclusivity and authenticity, AEO’s brands empower every customer to celebrate their unique personal style by offering casual, comfortable, timeless outfitting and high-quality products that are made to last.

AEO Inc. operates stores in the United States, Canada and Mexico, with merchandise available in more than 30 countries through a global network of license partners. Additionally, the company operates a robust e-commerce business across its brands. For more information, visit aeo-inc.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release and related statements by management contain forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), which represent management’s expectations or beliefs concerning future events, including, without limitation, fourth fiscal quarter and annual fiscal 2024 results. Words such as “outlook,” “estimate,” “project,” “plan,” “believe,” “expect,” “anticipate,” “intend,” “may,” “potential,” and similar expressions may identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements made by the company are inherently uncertain because they are based on assumptions and expectations concerning future events and are subject to change based on many important factors, some of which may be beyond the company’s control. Except as may be required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise and even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. The following factors, in addition to the risks disclosed in Item 1A., Risk Factors, of our Annual Report on Form 10-K for the fiscal year ended February 3, 2024 and in any other filings that we may make with the Securities and Exchange Commission, in some cases have affected, and in the future could affect, the company’s financial performance and could cause actual results to differ materially from those expressed or implied in any of the forward-looking statements included in this release or otherwise made by management: the risk that the company’s operating, financial and capital plans may not be achieved; our inability to anticipate customer demand and changing fashion trends and to manage our inventory commensurately; seasonality of our business; our inability to achieve planned store financial performance; our inability to react to raw material cost, labor and energy cost increases; our inability to gain market share in the face of declining shopping center traffic; our inability to respond to changes in e-commerce and leverage omni-channel demands; our inability to expand internationally; difficulty with our international merchandise sourcing strategies; challenges with information technology systems, including safeguarding against security breaches; and global economic, public health, social, political and financial conditions, and the resulting impact on consumer confidence and consumer spending, as well as other changes in consumer discretionary spending habits, which could have a material adverse effect on our business, results of operations and liquidity.

The use of the “company,” “AEO,” “we,” “us,” and “our” in this release refers to American Eagle Outfitters, Inc.

Line Media

412-432-3300

[email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Fashion Retail Consumer Women Teens Specialty Men

MEDIA:

Logo
Logo